Vantage logo

Reading Arcus’s Tigit tea leaves

As data non-disclosure prompts sellside guesswork one indisputable fact stands out: Gilead has not opted in to Arcus’s domvanalimab.

Vantage logo

CD47 is worth $4.9bn to Gilead

A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.